and for those EGRIFTA-treated patients completing the 26-week treatment period that were re-randomized to EGRIFTA (T-T group) or re-randomized to placebo, 37% and 32%, respectively, had impaired glucose tolerance, while 2% re-randomized to EGRIFTA and 6% re-randomized to placebo had diet-controlled type 2 diabetes mellitus
The role of conjugated linoleic acid in reducing body fat and preventing holiday weight gain
Exendin-4, a glucagon-like peptide 1 receptor agonist, protects cholangiocytes from apoptosis
Lancet Oncol 18(10):14111422 Franz DN et al (2013) Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial
Depending on the type of injection, patients often report improvements in energy, focus, and overall well-being